22 . 01 .2026
Press release
IMCAS 2026: Galderma showcases the latest scientific advances behind the industry’s broadest injectable aesthetics portfolio
21 . 01 .2026
Press release
Galderma provides update on arbitration case regarding neuromodulator research and development partnership
14 . 01 .2026
Press release
TOXINS 2026: Clinical updates on Galderma’s leading neuromodulator portfolio further reinforce its leadership in Injectable Aesthetics
17 . 12 .2025
Press release
New published data confirms Nemluvio® (nemolizumab) can rapidly relieve itch and improve sleep in as early as two days in both atopic dermatitis and prurigo nodularis
11 . 12 .2025
Press release
Galderma announces first patient enrollment in study to assess nemolizumab in adults with Chronic Pruritus of Unknown Origin
05 . 12 .2025
Press release
Galderma opens up new chapter for Sculptra® with MDR certification and new expanded indication for body
04 . 12 .2025
Press release
Galderma secures ‘BBB’ credit rating with positive outlook from S&P Global Ratings
17 . 11 .2025
Press release
ASDS 2025: Compelling new data on Restylane, Sculptra and Relfydess highlight Galderma’s innovative Injectable Aesthetics portfolio and pipeline
05 . 11 .2025
Press release
Galderma receives U.S. FDA approval for Restylane® Lyft™ for the enhancement of the chin profile